June 28, 2022

Volume XII, Number 179

Advertisement
Advertisement

June 27, 2022

Subscribe to Latest Legal News and Analysis

EPA Draws Link Between Low-Dose Formaldehyde Exposure and Cancer

On April 14, 2022, the United States Environmental Protection Agency released an updated draft risk assessment for formaldehyde, in which it links long-term, low-dose inhalation of the common chemical to leukemia and various cancers involving the head and neck.  EPA has also identified potential links to non-cancer health outcomes, including sensory irritation, respiratory problems, reproductive and developmental toxicity, and nervous system effects.  The risk assessment associates these potentially adverse health effects with lifetime doses even lower than those identified by EPA in its 2010 draft, which EPA had agreed to revisit after the scientific community and industry stakeholders criticized its methodology.

If the risk assessment is finalized, EPA will officially designate formaldehyde as a known human carcinogen for the first time.  Classification as a known human carcinogen could increase litigation risk for companies who manufacture formaldehyde or whose products may contain the chemical.  The classification could also invite new regulations or even bans under the Toxic Substances Control Act (TSCA), pursuant to which EPA is currently separately evaluating formaldehyde’s potential health and environmental risks.

The impact of EPA’s conclusions could be far-ranging—formaldehyde is commonly used in a wide range of industrial and consumer products, including carpeting, flooring, furniture, foam insulation, paints, wood glue, adhesives, cosmetics, and fragrances.  Given the potential business disruption and litigation threat, affected companies should carefully monitor the draft risk assessment as it proceeds through the public comment period and scientific review process.

Risk Assessment Conclusions

In the draft risk assessment, EPA has drawn conclusions about the weight of the evidence supporting a causal link between long-term formaldehyde exposure and various cancer and non-cancer health effects.  EPA’s judgments of the evidence regarding each potential health effect fall into four categories:

  • Evidence “demonstrating” a causal link. According to EPA, the evidence regarding each of the following health effects “signifies a very high level of certainty that formaldehyde exposure caused the health effect”:

    • Nasopharyngeal cancer

    • Myeloid leukemia

    • Sinonasal cancer

    • Sensory irritation

    • Respiratory tract pathology

  • Evidence “indicating” a causal link. According to EPA, the evidence regarding each of the following health effects “reflects a reasonable certainty that the relationship between formaldehyde exposure and the health outcome was causal, although there may be some outstanding questions that remain”:

    • Decreased pulmonary function

    • Allergic conditions

    • Current asthma symptoms or degree of asthma control

    • Female reproductive or developmental toxicity

    • Male reproductive toxicity

  • Evidence “suggesting” a causal link. According to EPA, the evidence regarding each of the following health effects “conveys some concern that formaldehyde may cause a particular health outcome, but there were very few studies that contributed to the evaluation, the evidence was very weak or conflicting, or the methodological conduct of the studies was poor”:

    • Oropharyngeal / hypopharyngeal cancer

    • Multiple myeloma

    • Hodgkin lymphoma

    • Nervous system effects

  • Evidence “inadequate” to make a determination. According to EPA, the evidence regarding each of the following health effects “conveys either a lack of information or an inability to interpret the available evidence” and “generally indicates that further research is needed”:

    • Laryngeal cancer

    • Lymphatic leukemia

Next Steps

EPA is accepting comments on the draft risk assessment through June 13, 2022.  Companies whose operations may be impacted by EPA’s conclusions should carefully monitor the comment docket and consider submitting their own comments.  Following the public comment period, the National Academies of Sciences, Engineering, and Medicine will conduct a full scientific review of the Agency’s findings.

Companies should also keep EPA’s ongoing TSCA risk evaluation for formaldehyde on their radars.  EPA’s draft IRIS risk assessment almost certainly foreshadows the conclusions EPA will reach in its TSCA risk evaluation.  EPA cannot issue regulations under its IRIS program, but it is authorized to regulate or even ban chemicals if unreasonable risks to human health or the environment are identified in a TSCA risk evaluation.  Although TSCA requires EPA to issue a final risk evaluation for formaldehyde by December 2022, the Agency has already indicated that it could be delayed at least until June 2023 and possibly as late as December 2024.

Copyright © 2022, Hunton Andrews Kurth LLP. All Rights Reserved.National Law Review, Volume XII, Number 110
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement

About this Author

Alexandra B. Cunningham Products Liability Attorney Richmond
Partner

Ms. Cunningham is co-head of the firm’s products liability and mass tort litigation practice group. She represents major corporate clients in all aspects of product liability, mass tort and toxic tort and environmental litigation, including successfully defending catastrophic injury and death claims; asbestos, benzene, formaldehyde, hydrogen sulfide, solvent and silica-related premises and product liability claims; large-scale environmental toxin and exposure claims, involving PFAS, PAHs, fluorides, coal combustion residuals and hexavalent chromium; and claims of bacterial contamination in...

+1 804 787 8087
Elizabeth Reese Product Liability Litigation Attorney Hunton Andrews Kurth Richmond, VA
Associate

Elizabeth helps companies navigate the complexities of product liability litigation and product safety regulation, providing insight into how strategic litigation decisions and comprehensive compliance programs can position companies for long-range success.

Elizabeth handles all aspects of product liability, mass tort, and toxic tort litigation. She has successfully defended companies facing high-stakes consumer product liability litigation and regularly represents clients in commercial and civil disputes. Elizabeth has substantial experience litigating claims involving...

804-787-8060
Advertisement
Advertisement
Advertisement